Counter-Narcotics Partnership: Inaugural Meeting Of The U.S.–India Drug Policy Working Group
SDG 3: Good Health and Well-being | SDG 16: Peace, Justice and Strong Institutions | SDG 17: Partnerships for the Goals
Narcotics Control Bureau (NCB) | Ministry of External Affairs (MEA)
From January 20–21, 2026, the United States hosted the inaugural meeting of the U.S.–India Drug Policy Executive Working Group in Washington, D.C.. This high-level dialogue, opened by Office of National Drug Control Policy (ONDCP) Director Sara Carter, fulfills a mutual commitment by President Trump and Prime Minister Modi to elevate counter-narcotics cooperation to a core national security priority. The discussions emphasized a “whole-of-government” approach to dismantle illegal production networks and eradicate the financial lifelines of narco-terrorism that threaten both nations.
Operationalizing Enforcement and Supply Chain Security The working group, led by the ONDCP and India’s Narcotics Control Bureau (NCB), identified several tangible areas for immediate action:
Combatting Synthetic Opioids: Both delegations reaffirmed a shared commitment to disrupting the trafficking of synthetic opioids and novel precursor chemicals.
Digital and Financial Disruption: Strategic focus was placed on the growing misuse of digital platforms and encrypted networks by drug cartels, particularly those utilizing cryptocurrency for illicit payments.
Pharmaceutical Supply Chain: The group committed to securing legitimate pharmaceutical supply chains to prevent the diversion of chemicals into illegal markets while ensuring the facilitation of lawful trade.
Intelligence Sharing: Building on recent joint operational successes, the two countries agreed to streamline interagency intelligence sharing to proactively disrupt global drug trafficking syndicates.
Balancing Enforcement with Trade Facilitation India’s Ambassador to the U.S., Vinay Kwatra, underscored that while narcotics trafficking remains a highest-priority threat, enforcement must be balanced with the facilitation of legitimate pharmaceutical industries. This dual focus aims to protect families and communities from the drug crisis without hindering the growth of India’s vital healthcare and chemical sectors.
What is “Narco-Terrorism” in the context of the U.S.-India partnership? Narco-terrorism refers to the symbiotic relationship between illegal drug trafficking and terrorist organizations, where the sale of narcotics provides the primary financial resources to fund insurgent and terrorist activities. In the U.S.-India context, this alliance represents a significant threat to regional stability and national security, necessitating joint operations to dismantle the financial networks that allow these groups to operate across borders.
Policy Relevance
The inaugural meeting of this working group signifies the institutionalization of counter-narcotics as a key pillar of the U.S.–India Major Defense Partnership.
National Security Integration: By classifying the drug crisis as a core national security priority, India can better coordinate its domestic enforcement agencies (NCB, NIA) with U.S. counterparts to target transboundary criminal networks.
Protecting the Pharmaceutical Hub: Securing the pharmaceutical supply chain protects the global reputation of the “Pharmacy of the World,” ensuring that India’s legitimate exports are not tainted by associations with illegal chemical diversion.
Technological Capability Building: Collaboration on disrupting crypto-funded cartels provides India with access to advanced U.S. forensic and digital tracking technologies, enhancing its capabilities to monitor the Dark Web.
Regional Stability: Stronger U.S.–India cooperation acts as a deterrent against narco-terrorist outfits in the neighborhood, contributing to broader Indo-Pacific security.
Relevant Question for Policy Stakeholders: How can the Narcotics Control Bureau (NCB) leverage the “tangible outcomes” of this working group to create a centralized, technology-driven monitoring system for the movement of precursor chemicals within India’s chemical clusters?
Follow the full news here: Inaugural Meeting of the U.S.-India Drug Policy Executive Working Group